Q-omics provides the consensus-scored PNPLA8 profile across patient tissues and cancer cell-line models. PNPLA8 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PNPLA8 is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, PNPLA8 RNA expression shows 19,729 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where PNPLA8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PNPLA8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PNPLA8 survival associations across molecular data types. PNPLA8 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (12) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PNPLA8 RNA expression–survival associations across cancer types. High PNPLA8 expression shows unfavorable associations in UVM and STAD, but favorable associations in KIRC, UCEC, LUAD and CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PNPLA8 RNA expression.
This table summarizes PNPLA8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 8. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PNPLA8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PNPLA8 shows lower tumor expression in THCA, KIRC, KIRP and UCEC and higher tumor expression in ESCA and HNSC. The THCA box plot shows higher PNPLA8 RNA expression in normal versus tumor tissue (log2 FC = −0.892, t-test p < 0.001).
This table shows molecular features associated with PNPLA8 in patient tissues and cancer cell lines. In patient samples, PNPLA8 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PNPLA8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
